Journal
MED
Volume 1, Issue 1, Pages 66-77Publisher
CELL PRESS
DOI: 10.1016/j.medj.2020.11.002
Keywords
-
Categories
Funding
- NIH [AI052733, AI15207, HL059842, R01AI123654, R01AI143453, DK111930]
- Mathers Foundation
- National Center for Advancing Translational Sciences (NCATS) [3UL1TR002556-04S1]
- BARDA [75A50120C00096]
- National Heart, Lung, and Blood Institute (NHLBI) [5R35HL139854]
- The Longer Life Foundation
Ask authors/readers for more resources
Antibody-based therapy for infectious diseases predates modern antibiotics and, in the absence of other therapeutic options, was deployed early in the SARS-CoV-2 pandemic through COVID-1 9 convalescent plasma (CCP) administration. Although most studies have demonstrated signals of efficacy for CCP, definitive assessment has proved difficult under pandemic conditions, with rapid changes in disease incidence and the knowledge base complicating the design and implementation of randomized controlled trials. Nevertheless, evidence from a variety of studies demonstrates that CCP is as safe as ordinary plasma and strongly suggests that it can reduce mortality if given early and with sufficient antibody content.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available